What is Zacks Research’s Forecast for Glaukos Q1 Earnings?

Glaukos Corporation (NYSE:GKOS) – Zacks Research lowered their Q1 2026 earnings per share estimates for shares of Glaukos in a research report issued on Monday, March 9th. Zacks Research analyst Team now forecasts that the medical instruments supplier will post earnings per share of ($0.27) for the quarter, down from their previous estimate of ($0.16). The consensus estimate for Glaukos’ current full-year earnings is ($1.08) per share. Zacks Research also issued estimates for Glaukos’ Q2 2026 earnings at ($0.24) EPS, Q3 2026 earnings at ($0.15) EPS, Q4 2026 earnings at ($0.01) EPS, FY2026 earnings at ($0.67) EPS, Q1 2027 earnings at ($0.10) EPS, Q2 2027 earnings at $0.09 EPS, Q3 2027 earnings at $0.10 EPS, Q4 2027 earnings at $0.33 EPS and FY2027 earnings at $0.42 EPS.

Glaukos (NYSE:GKOS) last announced its quarterly earnings data on Tuesday, February 17th. The medical instruments supplier reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.06). Glaukos had a negative net margin of 36.99% and a negative return on equity of 7.00%. The company had revenue of $143.12 million for the quarter, compared to analyst estimates of $132.16 million. During the same quarter in the prior year, the company posted ($0.40) EPS. Glaukos’s revenue for the quarter was up 35.6% on a year-over-year basis.

GKOS has been the subject of a number of other reports. Wall Street Zen downgraded Glaukos from a “buy” rating to a “hold” rating in a research report on Saturday, February 21st. Needham & Company LLC upped their price target on shares of Glaukos from $125.00 to $127.00 and gave the company a “buy” rating in a research note on Wednesday, February 18th. Citigroup raised their target price on Glaukos from $113.00 to $125.00 and gave the stock a “buy” rating in a research note on Thursday, December 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Glaukos in a research report on Thursday, January 22nd. Finally, Truist Financial upped their price objective on shares of Glaukos from $120.00 to $145.00 and gave the stock a “buy” rating in a research report on Thursday, December 18th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, Glaukos currently has an average rating of “Moderate Buy” and a consensus price target of $133.69.

Glaukos Stock Down 0.2%

Shares of NYSE:GKOS opened at $102.91 on Wednesday. The business’s 50 day moving average is $115.21 and its 200 day moving average is $101.19. Glaukos has a 12-month low of $73.16 and a 12-month high of $130.23. The stock has a market cap of $5.98 billion, a price-to-earnings ratio of -31.57 and a beta of 0.70. The company has a quick ratio of 4.06, a current ratio of 4.69 and a debt-to-equity ratio of 0.10.

Institutional Investors Weigh In On Glaukos

Several institutional investors and hedge funds have recently modified their holdings of the stock. Wellington Management Group LLP lifted its stake in shares of Glaukos by 10.4% in the 3rd quarter. Wellington Management Group LLP now owns 3,580,670 shares of the medical instruments supplier’s stock valued at $292,004,000 after purchasing an additional 336,266 shares during the period. Primecap Management Co. CA grew its position in Glaukos by 49.8% during the 4th quarter. Primecap Management Co. CA now owns 3,376,928 shares of the medical instruments supplier’s stock valued at $381,289,000 after purchasing an additional 1,123,140 shares during the last quarter. Janus Henderson Group PLC grew its holdings in shares of Glaukos by 183.4% during the fourth quarter. Janus Henderson Group PLC now owns 3,018,787 shares of the medical instruments supplier’s stock valued at $340,855,000 after buying an additional 1,953,578 shares during the last quarter. State Street Corp increased its holdings in shares of Glaukos by 0.9% in the 4th quarter. State Street Corp now owns 2,122,402 shares of the medical instruments supplier’s stock worth $239,640,000 after purchasing an additional 18,040 shares in the last quarter. Finally, Ameriprise Financial Inc. increased its holdings in Glaukos by 3.5% in the 2nd quarter. Ameriprise Financial Inc. now owns 1,999,252 shares of the medical instruments supplier’s stock worth $206,503,000 after buying an additional 68,497 shares in the last quarter. 99.04% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, Director Aimee S. Weisner sold 15,000 shares of the company’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $117.38, for a total transaction of $1,760,700.00. Following the completion of the transaction, the director directly owned 18,806 shares of the company’s stock, valued at approximately $2,207,448.28. This represents a 44.37% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Marc Stapley sold 15,000 shares of the stock in a transaction that occurred on Thursday, January 22nd. The stock was sold at an average price of $127.71, for a total value of $1,915,650.00. Following the completion of the sale, the director owned 37,449 shares of the company’s stock, valued at approximately $4,782,611.79. This trade represents a 28.60% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 320,000 shares of company stock valued at $37,202,909 over the last quarter. Company insiders own 5.80% of the company’s stock.

Glaukos News Roundup

Here are the key news stories impacting Glaukos this week:

• Positive Sentiment: Zacks published a bullish longer‑term view, initiating/issuing an FY2028 EPS forecast of $1.68, implying significant improvement versus the multi‑year loss trajectory and signaling potential upside if execution stays on track. MarketBeat: Zacks FY2028 estimate
• Neutral Sentiment: Zacks provided a full schedule of revised quarterly and annual estimates (Q1–Q4 2026, FY2026, Q1–Q4 2027, FY2027), which gives a clearer multi‑year earnings path but increases model dispersion versus the consensus (consensus full‑year EPS still shown at -$1.08). That creates both clarity and uncertainty for investors projecting valuation. MarketBeat: Zacks full estimate set
• Negative Sentiment: Zacks materially lowered near‑term estimates: Q1–Q4 2026 and several 2027 quarters were cut (examples: Q1 2026 to -$0.27 from -$0.16; Q2 2026 to -$0.24 from -$0.12; Q3 2026 to -$0.15 from -$0.05; Q4 2026 to -$0.01 from $0.04; Q1 2027 to -$0.10 from $0.01; Q2–Q3 2027 also down). Zacks reduced FY2026 to -$0.67 (from -$0.29) and cut FY2027 to $0.42 (from $0.78). Those downgrades push expected profitability further out and are the main driver of today’s share weakness. MarketBeat: Zacks cuts to near‑term EPS

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.